Showing 8041-8050 of 8822 results for "".
- Aclaris Initiates Phase 2b Trials of A-101 for Topical Treatment of Common Wartshttps://practicaldermatology.com/news/aclaris-initiates-phase-2b-trials-of-a-101-for-topical-treatment-of-common-warts/2458135/Aclaris Therapeutics, Inc. has initiated two Phase 2 clinical trials to evaluate A-101 45% topical solution (A-101 45%), an investigational drug for the treatment of common warts (verruca vulgaris). Over 22 million Americans have common warts, but there are currently no FDA-approved prescription
- Braun Survey: Many Men Fret About Sensitive Skinhttps://practicaldermatology.com/news/braun-survey-many-men-fret-over-sensitive-skin/2458133/Dry, sensitive or red skin is a major key cause for anxiety among UK men, and this often impedes upon their quality of life, according to a new survey from Braun. More than one in three (34 percent) of the 7,074 men surveyed described their sk
- No Need to Delay Certain Skin Procedures for Isotretinoin Patientshttps://practicaldermatology.com/news/no-need-to-delay-certain-skin-procedures-for-isotretinoin-patients/2458140/New consensus recommendations set the record straight on the timing of skin procedures for patients taking isotretinoin. After reviewing 32 relevant publications, the authors found “insufficient evidence” to support delaying manual dermabrasion, superficial chemical peels
- Survey: Despite Knowledge, Parents Don't Drive Kids' Sunscreen Usehttps://practicaldermatology.com/news/survey-despite-knowledge-parents-dont-drive-kids-sunscreen-use/2458142/According to a new Neutrogena Survey conducted online by Harris Poll, more than 4 in 5 parents of children under 18 years old say their children do not wear sunscreen on a daily basis— despite over 9 in 10 Americans believing sunscreen is important for protecting a child’s health.
- Study Tallies Adverse Events Reported to FDA for Cosmeticshttps://practicaldermatology.com/news/study-tallies-adverse-events-reported-to-fda-for-cosmetics/2458144/There were 5,144 adverse events reported to the US Food and Drug Administration (FDA) for cosmetics and personal care products from 2004 to 2016, an average of 396 events per year, according to a new research letter published by
- FDA Approves New Antibiotic for Skin Infectionshttps://practicaldermatology.com/news/fda-approves-new-antibiotic-for-skin-infections/2458149/The FDA has approved Melinta Therapeutics' Baxdela (delafloxacin) for adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible bacteria. Baxdela is a fluoroquinolone that exhibits activity against both gram-positive and gram-negative pathog
- EMA Grants Orphan Status to Tarix's EB Candidiatehttps://practicaldermatology.com/news/ema-grants-orphan-status-to-tarixs-eb-candidiate/2458160/The European Medicines Agency (EMA) granted Orphan Drug status to Tarix Orphan LLC’s lead compound, TXA127, for the treatment of epidermolysis bullosa (EB). TXA127 is a pharmaceutical grade formulation of the naturally occurring peptide
- Retailers Charge Women More Than Men for Minoxidilhttps://practicaldermatology.com/news/retailers-charge-women-more-than-men-for-minoxidil/2458163/Women pay an average of 40 percent more than men for minoxidil foams, according to a new analysis from researchers at the Perelman School of Medicine at the University of Pennsylvania in JAMA Dermatology</
- Tildrakizumab Performs Well in Two Phase 3 Psoriasis Studieshttps://practicaldermatology.com/news/tildrakizumab-performs-well-in-two-phase-3-psoriasis-studies/2458164/Two Phase 3 trials show that tildrakizumab is efficacious and well-tolerated in patients with moderate-to-severe chronic plaque psoriasis. Specifically more than 60 percent of all patients who received the active medication showed improvement, compared to less than 10 percent of patients
- First Patient Enrolled in DELIVERS Study of Diacerein 1% Ointment for EBShttps://practicaldermatology.com/news/first-patient-enrolled-in-delivers-study-of-diacerein-1-ointment-for-ebs/2458168/The first patient has enrolled in Castle Creek Pharmaceuticals (CCP) Phase 2/3 DELIVERS clinical trial evaluating the safety and efficacy of diacerein 1% ointment (CCP-020) for the treatment of epidermolysis bull